X-Linked Chronic Granulomatous Disease: Initial Presentation with Intracranial Hemorrhage from Vitamin K Deficiency in Infant

Boonchai Boonyawat, Yiwa Suksawat, Punchama Pacharn, Piradee Suwanpakdee, Chanchai Traivaree, Boonchai Boonyawat, Yiwa Suksawat, Punchama Pacharn, Piradee Suwanpakdee, Chanchai Traivaree

Abstract

Vitamin K deficiency bleeding (VKDB) is a life-threatening condition and can be found in children as early as neonatal period with early onset intracranial hemorrhage (ICH). Here, we reported a 1-year-old boy who initially presented with intracranial hemorrhage secondary to vitamin K deficiency since 3 months of age and later found to have XL-CGD which was complicated by malabsorption due to severe vaccine-associated mycobacterial disease.

Figures

Figure 1
Figure 1
(a) CT brain showed hyperdensity lesion size of 1.5 × 1.8 cm at the left temporal lobe. (b) Chest X-ray revealed patchy infiltration at the left upper lobe.
Figure 2
Figure 2
The DHR assay of the patient showed complete absence of DHR shift after granulocyte stimulation. The SI was 1.21 which was compatible with XL-CGD. The DHR assay of the patient's mother showed bimodal distribution which was compatible with the XL-CGD carrier. The stimulation index (SI) was calculated by dividing the mean channel of fluorescence intensity in the stimulated cell over the mean channel of fluorescence intensity in the unstimulated cell.
Figure 3
Figure 3
Electropherogram of the exon 7 of CYBB gene revealed a hemizygous c.676C > T (p.Arg226Ter) nonsense mutation in the patient's DNA (a), a heterozygous for the same mutation in the maternal DNA (b), and normal DNA sequence (c).

References

    1. Winkelstein J. A., Marino M. C., Johnston R. B., Jr., et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine. 2000;79(3):155–169. doi: 10.1097/00005792-200005000-00003.
    1. van den Berg J. M., van Koppen E., Ahlin A., et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4) doi: 10.1371/journal.pone.0005234.e5234
    1. Ishibashi F., Nunoi H., Endo F., Matsuda I., Kanegasaki S. Statistical and mutational analysis of chronic granulomatous disease in Japan with special reference to gp91-phox and p22-phox deficiency. Human Genetics. 2000;106(5):473–481. doi: 10.1007/s004390000288.
    1. Wu J., Wang W. F., Zhang Y. D., Chen T. X. Clinical Features and genetic analysis of 48 patients with chronic granulomatous disease in a Single Center Study from Shanghai, China (2005–2015): new studies and a literature review. Journal of Immunology Research. 2017;2017:17. doi: 10.1155/2017/8745254.8745254
    1. Marciano B. E., Rosenzweig S. D., Kleiner D. E., et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462–468. doi: 10.1542/peds.114.2.462.
    1. Huang A., Abbasakoor F., Vaizey C. J. Gastrointestinal manifestations of chronic granulomatous disease. Colorectal Disease. 2006;8(8):637–644. doi: 10.1111/j.1463-1318.2006.01030.x.
    1. Jirapongsananuruk O., Malech H. L., Kuhns D. B., et al. Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay. Journal of Allergy and Clinical Immunology. 2003;111(2):374–379. doi: 10.1067/mai.2003.58.
    1. Grange J. M. Complications of bacille Calmette-Guerin (BCG) vaccination and immunotherapy and their management. Communicable Disease and Public Health. 1998;1(2):84–88.
    1. Ying W., Sun J., Liu D., et al. Clinical characteristics and immunogenetics of BCGosis/BCGitis in Chinese children: a 6 year follow-up study. PLoS One. 2014;9(4) doi: 10.1371/journal.pone.0094485.e94485
    1. Norouzi S., Aghamohammadi A., Mamishi S., Rosenzweig S. D., Rezaei N. Bacillus Calmette-Guerin (BCG) complications associated with primary immunodeficiency diseases. Journal of Infection. 2012;64(6):543–554. doi: 10.1016/j.jinf.2012.03.012.
    1. Roos D., Kuhns D. B., Maddalena A., et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update) Blood Cells, Molecules and Diseases. 2010;45(3):246–265. doi: 10.1016/j.bcmd.2010.07.012.
    1. Jakobsen M. A., Katzenstein T. L., Valerius N. H., et al. Genetical analysis of all Danish patients diagnosed with chronic granulomatous disease. Scandinavian Journal of Immunology. 2012;76(5):505–511. doi: 10.1111/j.1365-3083.2012.02771.x.
    1. Vilaiphan P., Chatchatee P., Ngamphaiboon J., Tongkobpetch S., Suphapeetiporn K., Shotelersuk V. Nonsense mutations of the CYBB gene in two Thai families with X-linked chronic granulomatous disease. Asian Pacific Journal of Allergy and Immunology. 2007;25(4):243–247.
    1. Jirapongsananuruk O., Noack D., Boonchoo S., et al. A novel mutation of the CYBB gene resulting in severe form of X-linked chronic granulomatous disease. Asian Pacific Journal of Allergy and Immunology. 2007;25(4):249–252.
    1. Martire B., Rondelli R., Soresina A., et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clinical Immunology. 2008;126(2):155–164. doi: 10.1016/j.clim.2007.09.008.
    1. Khandelwal P., Bleesing J. J., Davies S. M., Marsh R. A. A single-center experience comparing alemtuzumab, fludarabine, and melphalan reduced-intensity, conditioning with myeloablative busulfan, cyclophosphamide, and antithymocyte globulin for chronic granulomatous disease. Biology of Blood and Marrow Transplantation. 2016;22(11):2011–2018. doi: 10.1016/j.bbmt.2016.08.013.
    1. Morillo-Gutierrez B., Beier R., Rao K., et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128(3):440–448. doi: 10.1182/blood-2016-03-704015.
    1. Gungor T., Teira P., Slatter M., et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. The Lancet. 2014;383(9915):436–448. doi: 10.1016/s0140-6736(13)62069-3.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe